Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532372 | 0.99 | MBOAT4 (0.49) | MBOAT4TRPV1PTGS1CDK2KDR | |
| SCHEMBL2530336 | 0.97 | MBOAT4 (0.53) | MBOAT4TRPV1PTGS1CDK2KDR | |
| SCHEMBL2527370 | 0.89 | TRPV1 (0.46) | MBOAT4TRPV1PTGS1CDK2KDR | |
| SCHEMBL14797550 | 0.88 | MBOAT4 (0.43) | MBOAT4TRPV1 | |
| SCHEMBL2527209 | 0.88 | TRPV1 (0.47) | MBOAT4TRPV1 | |
| SCHEMBL2530815 | 0.88 | TRPV1 (0.47) | MBOAT4TRPV1PTGS1LOXL2 | |
| SCHEMBL2532178 | 0.88 | TRPV1 (0.47) | MBOAT4TRPV1PTGS1CDK2KDR | |
| SCHEMBL2531204 | 0.86 | TRPV1 (0.44) | MBOAT4TRPV1PTGS1CDK2KDR | |
| SCHEMBL2531618 | 0.85 | TRPV1 (0.49) | MBOAT4TRPV1 | |
| SCHEMBL2531610 | 0.85 | TRPV1 (0.49) | MBOAT4TRPV1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760837-A1 | SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| WO-2013045452-A1 | SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045452-A1 | SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079373-A1 | Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079373-A1 | Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1940821-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | MBOAT4 1687/4885TRPV1 1/4885PTGS1 1704/4885 |
| US-20130079373-A1 | Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPV3, TRPA1 | MBOAT4 1080/4885TRPV1 1/4885PTGS1 539/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | MBOAT4 1687/4885TRPV1 1/4885PTGS1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.